BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37776978)

  • 1. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab.
    Atsou S; Schellenberg C; Lagrange J; Lacolley P; Lenting PJ; Denis CV; Christophe OD; Regnault V
    J Thromb Haemost; 2024 Jan; 22(1):112-125. PubMed ID: 37776978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
    Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
    Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma.
    Yada K; Ogiwara K; Shimonishi N; Nakajima Y; Soeda T; Kitazawa T; Nogami K
    Int J Hematol; 2024 Feb; 119(2):109-118. PubMed ID: 38112996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab.
    Yamaguchi T; Shinozawa K; Nagatoishi S; Mitsuhashi A; Bingo M; Inaba H; Amano K; Tsumoto K; Kinai E
    Thromb Res; 2023 Feb; 222():131-139. PubMed ID: 36657269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
    Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-additive effect on thrombin generation when a plasma-derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitro.
    Bravo MI; Raventós A; Pérez A; Costa M; Willis T
    J Thromb Haemost; 2020 Aug; 18(8):1934-1939. PubMed ID: 32379931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab.
    Ogiwara K; Furukawa S; Shinohara S; Tabuchi Y; Arai N; Noguchi-Sasaki M; Soeda T; Shima M; Nogami K
    Haemophilia; 2023 Jan; 29(1):329-335. PubMed ID: 36137299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of emicizumab and recombinant factor VIII in plasma: Which assays can we use for accurate measurement?
    Bowyer AE; Maclean RM; Kitchen S
    Int J Lab Hematol; 2023 Jun; 45(3):368-376. PubMed ID: 36710421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro effects of emicizumab on activated clotting time in blood samples from cardiac surgical patients.
    Tanaka KA; Henderson R; Thangaraju K; Morita Y; Mazzeffi MA; Strauss E; Katneni U; Buehler PW
    Haemophilia; 2022 Jan; 28(1):183-190. PubMed ID: 34735039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays.
    Lund J; Jensen K; Burnier L; Ezban M
    J Thromb Haemost; 2023 Jun; 21(6):1493-1502. PubMed ID: 37037699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab.
    Valls R; Wagg J; Paz-Priel I; Man G; Artigas L; Jaccard G; Coma M; Schmitt C
    Sci Rep; 2023 Jun; 13(1):10078. PubMed ID: 37344529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
    Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional determination of emicizumab in presence of factor VIII activity.
    Hamedani NS; Donners AAMT; van Luin M; Gasper S; Rühl H; Klein C; Albert T; El Amrani M; Pötzsch B; Oldenburg J; Müller J
    J Thromb Haemost; 2023 Dec; 21(12):3490-3500. PubMed ID: 37741510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor.
    van 't Veer C; Hackeng TM; Delahaye C; Sixma JJ; Bouma BN
    Blood; 1994 Aug; 84(4):1132-42. PubMed ID: 8049429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.
    Yada K; Nogami K; Shinozawa K; Kitazawa T; Hattori K; Amano K; Fukutake K; Shima M
    Br J Haematol; 2018 Oct; 183(2):257-266. PubMed ID: 30125997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A hemophilia A mouse model for the in vivo assessment of emicizumab function.
    Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV
    Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence.
    Leksa NC; Aleman MM; Goodman AG; Rabinovich D; Peters R; Salas J
    J Thromb Haemost; 2019 Jul; 17(7):1044-1052. PubMed ID: 30887655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emicizumab promotes factor Xa generation on endothelial cells.
    Fager AM; Ellsworth P; Key NS; Monroe DM; Hoffman M
    J Thromb Haemost; 2024 Jun; 22(6):1605-1615. PubMed ID: 38460838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.
    Kizilocak H; Marquez-Casas E; Malvar J; Carmona R; Young G
    Haemophilia; 2021 Sep; 27(5):730-735. PubMed ID: 34115433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.